Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Axel Grothey

Showing results (81-90 of 303) with videos related to

Pageof 31
Sort By:
NEJM Evidence|February 24, 2026
Medical Treatment Options in Colorectal Cancer - Expanding the EvidenceAlena Annbalou Hasenburg, Axel Grothey
JAMA Oncology|May 8, 2020
Efficacy of Immunotherapy in Microsatellite-Stable or Mismatch Repair Proficient Colorectal Cancer-Fact or Fiction?Ryan B Corcoran, Axel Grothey
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 24, 2005
FOLFOX for stage II colon cancer? A commentary on the recent FDA approval of oxaliplatin for adjuvant therapy of stage III colon cancerAxel Grothey, Daniel J Sargent
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 5, 2012
Explaining the unexplainable: EGFR antibodies in colorectal cancerAxel Grothey, Heinz-Josef Lenz
Gastrointestinal Cancer Research : GCR|February 28, 2012
Waiting in line for cancer treatments?Wilson I Gonsalves, Axel Grothey
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 17, 2009
Biomarkers of Resistance to Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients with Metastatic Colorectal CancerMichaela S Banck, Axel Grothey
Nature Reviews. Clinical Oncology|January 7, 2015
Colorectal cancer in 2014: progress in defining first-line and maintenance therapiesJoleen M Hubbard, Axel Grothey
Nature Reviews. Clinical Oncology|May 13, 2015
Gastrointestinal cancer: Rationale for metronomic chemotherapy in phase III trialsRobert S Kerbel, Axel Grothey
JAMA|September 22, 2011
Time to initiation of adjuvant chemotherapy and survival in colorectal cancerDaniel Sargent, Axel Grothey, Richard Gray
The New England Journal of Medicine|February 27, 2020
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer. ReplyScott Kopetz, Axel Grothey, Josep Tabernero
Pageof 31

Showing results (81-90 of 303) with videos related to

Sort By:
Pageof 31
NEJM Evidence|February 24, 2026
Medical Treatment Options in Colorectal Cancer - Expanding the EvidenceAlena Annbalou Hasenburg, Axel Grothey
JAMA Oncology|May 8, 2020
Efficacy of Immunotherapy in Microsatellite-Stable or Mismatch Repair Proficient Colorectal Cancer-Fact or Fiction?Ryan B Corcoran, Axel Grothey
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 24, 2005
FOLFOX for stage II colon cancer? A commentary on the recent FDA approval of oxaliplatin for adjuvant therapy of stage III colon cancerAxel Grothey, Daniel J Sargent
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 5, 2012
Explaining the unexplainable: EGFR antibodies in colorectal cancerAxel Grothey, Heinz-Josef Lenz
Gastrointestinal Cancer Research : GCR|February 28, 2012
Waiting in line for cancer treatments?Wilson I Gonsalves, Axel Grothey
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 17, 2009
Biomarkers of Resistance to Epidermal Growth Factor Receptor Monoclonal Antibodies in Patients with Metastatic Colorectal CancerMichaela S Banck, Axel Grothey
Nature Reviews. Clinical Oncology|January 7, 2015
Colorectal cancer in 2014: progress in defining first-line and maintenance therapiesJoleen M Hubbard, Axel Grothey
Nature Reviews. Clinical Oncology|May 13, 2015
Gastrointestinal cancer: Rationale for metronomic chemotherapy in phase III trialsRobert S Kerbel, Axel Grothey
JAMA|September 22, 2011
Time to initiation of adjuvant chemotherapy and survival in colorectal cancerDaniel Sargent, Axel Grothey, Richard Gray
The New England Journal of Medicine|February 27, 2020
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer. ReplyScott Kopetz, Axel Grothey, Josep Tabernero
Pageof 31